MONTREAL and CHARLOTTE, N.C., Nov. 11, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and ...
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST ™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data ...
- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral ...
MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 ...
To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's website at www.milestonepharma.com. To access the live call by phone, ...
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
- Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 - Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results